Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.